Remus Pharmaceuticals Management
Management criteria checks 3/4
Remus Pharmaceuticals' CEO is Arpit Shah, appointed in Jan 2023, has a tenure of 2.08 years. directly owns 0.053% of the company’s shares, worth ₹6.46M. The average tenure of the management team and the board of directors is 2.1 years and 4.9 years respectively.
Key information
Arpit Shah
Chief executive officer
₹16.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
We Ran A Stock Scan For Earnings Growth And Remus Pharmaceuticals (NSE:REMUS) Passed With Ease
Sep 25
Remus Pharmaceuticals Limited's (NSE:REMUS) P/E Is Still On The Mark Following 28% Share Price Bounce
Aug 20Returns On Capital Signal Tricky Times Ahead For Remus Pharmaceuticals (NSE:REMUS)
Jun 27Concerns Surrounding Remus Pharmaceuticals' (NSE:REMUS) Performance
May 23Remus Pharmaceuticals Limited (NSE:REMUS) Looks Just Right With A 29% Price Jump
May 21CEO
Arpit Shah (37 yo)
2.1yrs
Tenure
₹16,800,000
Compensation
Mr. Arpit Deepakkumar Shah is Non-Executive & Non-Independent Director of Senores Pharmaceuticals Limited from February 19, 2024. Mr. Shah was Additional Non-Executive & Non-Independent Director of Senores...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.4yrs | ₹9.60m | 16.97% ₹ 2.1b | |
| MD & Director | 2.1yrs | ₹16.80m | 0.053% ₹ 6.5m | |
| Chief Financial Officer | 2.1yrs | ₹1.65m | 0.014% ₹ 1.6m | |
| Company Secretary & Compliance Officer | 2.1yrs | ₹820.00k | 0.24% ₹ 28.7m | |
| Whole Time Director | 2.1yrs | ₹9.00m | 17.18% ₹ 2.1b | |
| Whole Time Director | 4.2yrs | ₹6.00m | 16.97% ₹ 2.1b |
2.1yrs
Average Tenure
37yo
Average Age
Experienced Management: REMUS's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.4yrs | ₹9.60m | 16.97% ₹ 2.1b | |
| MD & Director | 9.4yrs | ₹16.80m | 0.053% ₹ 6.5m | |
| Whole Time Director | 9.4yrs | ₹9.00m | 17.18% ₹ 2.1b | |
| Whole Time Director | 4.9yrs | ₹6.00m | 16.97% ₹ 2.1b | |
| Non- Executive Independent Director | 2.1yrs | ₹140.00k | 0.14% ₹ 16.4m | |
| Non- Executive Independent Director | 2.1yrs | ₹140.00k | no data | |
| Non- Executive Independent Director | 2.1yrs | ₹170.00k | 0.27% ₹ 32.8m |
4.9yrs
Average Tenure
37yo
Average Age
Experienced Board: REMUS's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 06:51 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Remus Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.